

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

ZURICH
SWITZERLAND

10-11 MAY 2019

Co-Chairs

John B.A.G. Haanen, NL
Solange Peters, CH
Rolf A. Stahel, CH

ESMO PRECEPTORSHIP PROGRAMME

IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

Zurich, Switzerland
10-11 May 2019

CO-CHAIRS:

John B.A.G. Haanen, Netherlands
Solange Peters, Switzerland
Rolf A. Stahel, Switzerland

SPEAKERS:

Fabrice André, France	Michel Obeid, Switzerland
Sabine Blum, Switzerland	Camillo Porta, Italy
Andrés Cervantes, Spain	Pedro Romero, Switzerland
Alessandra Curioni, Switzerland	Patrick Roth, Switzerland
Mitchell Levesque, Switzerland	Cristiana Sessa, Switzerland
Bart Neyns, Belgium	

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their applications in cancer medicine
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Bristol-Myers Squibb



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 10 May 2019

09:00-10:35 95'	SESSION 1 Essentials of tumour immunology	Chair: Rolf A. Stahel, CH
40'	From basic to tumour immunology for oncologists	Pedro Romero, CH
40'	From translational research to clinical application	John B.A.G. Haanen, NL
15'	Discussion	Faculty
10:35-11:00	Coffee break	
11:00-12:15 75'	SESSION 2 Essentials in immunotherapies	Chair: John B.A.G. Haanen, NL
30'	Developments in immune checkpoint inhibition	Alessandra Curioni, CH
30'	Developments in adoptive T-Cell transfer	John B.A.G. Haanen, NL
15'	Discussion	Faculty
12:15-13:15	Lunch	
13:15-14:25 70'	SESSION 3 Clinical development	Chair: Solange Peters, CH
25'	Breast cancer	Fabrice André, FR
30'	Bladder and renal cell cancer	Camillo Porta, IT
15'	Discussion	Faculty
14:25-15:30 65'	SESSION 4 Melanoma	Chair: Solange Peters, CH
25'	Immune checkpoints	Bart Neyns, BE
25'	Combination therapies	Bart Neyns, BE
15'	Discussion	Faculty
15:30-16:00	Coffee break	
16:00-17:05 65'	SESSION 5 Clinical development	Chair: Rolf A. Stahel, CH
25'	Immunotherapy of gastrointestinal cancers	Andrés Cervantes, ES
25'	Gynaecological malignancies	Cristiana Sessa, CH
15'	Discussion	Faculty
17:05-17:45 40'	SESSION 6 Audience cases	Chair: John B.A.G. Haanen, NL
40'	Participants clinical case discussion (4x10')	Faculty
19:30	Dinner	

Saturday, 11 May 2019

08:30-09:10 40'	SESSION 7 Audience cases	Chair: Rolf A. Stahel, CH
40'	Participants clinical case discussion (4x10')	Faculty
09:10-10:15 65'	SESSION 8 Lung cancer and thoracic cancer	Chair: Solange Peters, CH
25'	Advanced Non-Small-Cell Lung Cancer (NSCLC)	Solange Peters, CH
25'	Early stage NSCLC, SCLC and mesothelioma	Rolf A. Stahel, CH
15'	Discussion	Faculty
10:15-10:55 40'	SESSION 9 Immunomonitoring and tumour antigens	Chair: Rolf A. Stahel, CH
30'	Biomarkers for immunotherapy	Mitchell Levesque, CH
10'	Discussion	Faculty
10:55-11:25	Coffee break	
11:25-12:30 65'	SESSION 10 Clinical development	Chair: Solange Peters, CH
25'	Haemato-oncology	Sabine Blum, CH
25'	Glioblastoma	Patrick Roth, CH
15'	Discussion	Faculty
12:30-13:05 35'	SESSION 11 Trial design and management of toxicities	Chair: John B.A.G. Haanen, NL
25'	Management of toxicities	Michel Obeid, CH
10'	Discussion	Faculty
13:05-13:15 10'	General discussion	John B.A.G. Haanen, NL Solange Peters, CH Rolf A. Stahel, CH
13:15-14:15	Lunch	

Note: Each 10 minutes slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion